SUMATRIPTAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sumatriptan, and when can generic versions of Sumatriptan launch?
Sumatriptan is a drug marketed by Adaptis, Cipla, Lannett Co Inc, Padagis Israel, Aurobindo Pharma Ltd, Rising, Sun Pharm, Antares Pharma Inc, Baxter Hlthcare Corp, Caplin, Dr Reddys, Endo Operations, Eugia Pharma, Fresenius Kabi Usa, Hikma, Norvium Bioscience, Sandoz, Steriscience Speclts, Teva Parenteral, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Zydus, Aurobindo Pharma, Corepharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, and Watson Labs. and is included in forty-one NDAs.
The generic ingredient in SUMATRIPTAN is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sumatriptan
A generic version of SUMATRIPTAN was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SUMATRIPTAN?
- What are the global sales for SUMATRIPTAN?
- What is Average Wholesale Price for SUMATRIPTAN?
Summary for SUMATRIPTAN
| US Patents: | 0 |
| Applicants: | 35 |
| NDAs: | 41 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| Clinical Trials: | 115 |
| Patent Applications: | 5,382 |
| Drug Prices: | Drug price information for SUMATRIPTAN |
| Drug Sales Revenues: | Drug sales revenues for SUMATRIPTAN |
| What excipients (inactive ingredients) are in SUMATRIPTAN? | SUMATRIPTAN excipients list |
| DailyMed Link: | SUMATRIPTAN at DailyMed |
See drug prices for SUMATRIPTAN
Recent Clinical Trials for SUMATRIPTAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Canisius-Wilhelmina Hospital | Phase 2 |
| Leiden University Medical Center | Phase 2 |
| ZonMw: The Netherlands Organisation for Health Research and Development | Phase 2 |
Pharmacology for SUMATRIPTAN
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Medical Subject Heading (MeSH) Categories for SUMATRIPTAN
Anatomical Therapeutic Chemical (ATC) Classes for SUMATRIPTAN
US Patents and Regulatory Information for SUMATRIPTAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | SUMATRIPTAN SUCCINATE | sumatriptan succinate | TABLET;ORAL | 076933-003 | Aug 10, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Dr Reddys Labs Inc | SUMATRIPTAN SUCCINATE | sumatriptan succinate | TABLET;ORAL | 076847-002 | Aug 10, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Wockhardt | SUMATRIPTAN SUCCINATE | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 078593-001 | Feb 6, 2009 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for SUMATRIPTAN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Galpharm Healthcare Ltd. | Sumatriptan Galpharm | sumatriptan | EMEA/H/C/002140 |
Refused | yes | no | no | 2012-02-09 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
